NASDAQ:FOMX - Foamix Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$3.81 -0.19 (-4.75 %)
(As of 12/11/2018 04:00 PM ET)
Previous Close$4.00
Today's Range$3.76 - $4.08
52-Week Range$3.60 - $7.60
Volume501,335 shs
Average Volume390,495 shs
Market Capitalization$222.02 million
P/E Ratio-2.16
Dividend YieldN/A
Beta2.08
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus. The company is also developing FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea; and FDX104 that has completed Phase II clinical trial for the treatment of chemotherapy-induced rash. Foamix Pharmaceuticals Ltd. has development and license agreements with Bayer HealthCare AG; Mylan N.V.; and Actavis Laboratories. The company was founded in 2003 and is headquartered in Rehovot, Israel.

Receive FOMX News and Ratings via Email

Sign-up to receive the latest news and ratings for FOMX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Medicinals & botanicals
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FOMX
Previous Symbol
CUSIPN/A
Phone972-8931-6233

Debt

Debt-to-Equity RatioN/A
Current Ratio12.41
Quick Ratio12.41

Price-To-Earnings

Trailing P/E Ratio-2.16
Forward P/E Ratio-2.28
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.67 million
Price / Sales56.35
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.83 per share
Price / Book2.08

Profitability

EPS (Most Recent Fiscal Year)($1.76)
Net Income$-65,710,000.00
Net Margins-2,049.92%
Return on Equity-118.29%
Return on Assets-99.30%

Miscellaneous

Employees75
Outstanding Shares54,280,000
Market Cap$222.02 million
OptionableOptionable

Foamix Pharmaceuticals (NASDAQ:FOMX) Frequently Asked Questions

What is Foamix Pharmaceuticals' stock symbol?

Foamix Pharmaceuticals trades on the NASDAQ under the ticker symbol "FOMX."

How were Foamix Pharmaceuticals' earnings last quarter?

Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) announced its quarterly earnings data on Wednesday, November, 7th. The specialty pharmaceutical company reported ($0.38) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.07. The specialty pharmaceutical company earned $0.87 million during the quarter, compared to analyst estimates of $1.10 million. Foamix Pharmaceuticals had a negative net margin of 2,049.92% and a negative return on equity of 118.29%. View Foamix Pharmaceuticals' Earnings History.

When is Foamix Pharmaceuticals' next earnings date?

Foamix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, February 27th 2019. View Earnings Estimates for Foamix Pharmaceuticals.

What price target have analysts set for FOMX?

4 brokers have issued 12-month price targets for Foamix Pharmaceuticals' stock. Their predictions range from $8.00 to $30.00. On average, they expect Foamix Pharmaceuticals' stock price to reach $16.6667 in the next year. This suggests a possible upside of 332.9% from the stock's current price. View Analyst Price Targets for Foamix Pharmaceuticals.

What is the consensus analysts' recommendation for Foamix Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Foamix Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Foamix Pharmaceuticals.

Has Foamix Pharmaceuticals been receiving favorable news coverage?

Media headlines about FOMX stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Foamix Pharmaceuticals earned a news impact score of 1.5 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the near term.

Who are some of Foamix Pharmaceuticals' key competitors?

Who are Foamix Pharmaceuticals' key executives?

Foamix Pharmaceuticals' management team includes the folowing people:
  • Mr. David T. Domzalski, CEO, Director & Pres of Foamix Pharmaceuticals Inc. (Age 51)
  • Mr. Meir Eini, Co-Founder & Innovation Advisor (Age 63)
  • Mr. Ilan Hadar MBA, CFO & Country Mang. (Age 49)
  • Mr. Yohan Hazot, VP of Pharmaceutical Devel. (Age 35)
  • Ms. Mutya Harsch, Gen. Counsel & Sr. VP of Legal Affairs

Who are Foamix Pharmaceuticals' major shareholders?

Foamix Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (5.72%), Franklin Resources Inc. (4.28%), AXA (2.61%), Point72 Asset Management L.P. (2.13%), Sio Capital Management LLC (1.42%) and Nexthera Capital LP (1.38%). Company insiders that own Foamix Pharmaceuticals stock include Aharon Schwartz, Alvin D Howard, David Domzalski, Iain Stuart, Meir Eini, Russell P Elliott and Stanley Hirsch. View Institutional Ownership Trends for Foamix Pharmaceuticals.

Which institutional investors are selling Foamix Pharmaceuticals stock?

FOMX stock was sold by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Vivo Capital LLC, Tekla Capital Management LLC and Sofinnova Ventures Inc. Company insiders that have sold Foamix Pharmaceuticals company stock in the last year include Alvin D Howard, David Domzalski, Iain Stuart, Meir Eini, Russell P Elliott and Stanley Hirsch. View Insider Buying and Selling for Foamix Pharmaceuticals.

Which institutional investors are buying Foamix Pharmaceuticals stock?

FOMX stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Point72 Asset Management L.P., Franklin Resources Inc., Sio Capital Management LLC, Nexthera Capital LP, C WorldWide Group Holding A S, First Manhattan Co. and Stonepine Capital Management LLC. View Insider Buying and Selling for Foamix Pharmaceuticals.

How do I buy shares of Foamix Pharmaceuticals?

Shares of FOMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Foamix Pharmaceuticals' stock price today?

One share of FOMX stock can currently be purchased for approximately $3.85.

How big of a company is Foamix Pharmaceuticals?

Foamix Pharmaceuticals has a market capitalization of $222.02 million and generates $3.67 million in revenue each year. The specialty pharmaceutical company earns $-65,710,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Foamix Pharmaceuticals employs 75 workers across the globe.

What is Foamix Pharmaceuticals' official website?

The official website for Foamix Pharmaceuticals is http://www.foamix.com.

How can I contact Foamix Pharmaceuticals?

Foamix Pharmaceuticals' mailing address is 2 HOLZMAN ST. WEIZMANN SCIENCE PARK, REHOVOT L3, 76704. The specialty pharmaceutical company can be reached via phone at 972-8931-6233 or via email at [email protected]


MarketBeat Community Rating for Foamix Pharmaceuticals (NASDAQ FOMX)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  180 (Vote Underperform)
Total Votes:  353
MarketBeat's community ratings are surveys of what our community members think about Foamix Pharmaceuticals and other stocks. Vote "Outperform" if you believe FOMX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FOMX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/11/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel